Abstract
Systemic cytokine inhibition may be an effective therapeutic strategy for several autoimmune diseases. However, recent studies suggest that tissue or cell type-specific targeting of certain cytokines, including TNF, may have distinct advantages and show fewer side effects. Here we describe protocols for generating and testing bispecific cytokine inhibitors using variable domain of single-chain antibodies from Camelidae (VHH) with a focus on cell-specific TNF inhibitors.
Keywords:
Anti-cytokine therapy; Bispecific antibody; Camelidae; TNF; VHH.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibody Affinity
-
Antibody Specificity
-
Cytokines / biosynthesis
-
Flow Cytometry
-
Immunoglobulin Heavy Chains* / genetics
-
Immunoglobulin Variable Region* / genetics
-
Single-Domain Antibodies / biosynthesis*
-
Single-Domain Antibodies / chemistry
-
Single-Domain Antibodies / isolation & purification
-
Single-Domain Antibodies / pharmacology
-
Tumor Necrosis Factor Inhibitors* / chemistry
-
Tumor Necrosis Factor Inhibitors* / isolation & purification
-
Tumor Necrosis Factor Inhibitors* / pharmacology
-
Tumor Necrosis Factors / chemistry
-
Tumor Necrosis Factors / metabolism
Substances
-
Cytokines
-
Immunoglobulin Heavy Chains
-
Immunoglobulin Variable Region
-
Single-Domain Antibodies
-
Tumor Necrosis Factor Inhibitors
-
Tumor Necrosis Factors